For over three decades, the 340B Drug Pricing Program has been a cornerstone in the United States' healthcare system, providing vital financial support to hospitals and clinics serving low-income and uninsured populations. By mandating pharmaceutical manufacturers to sell outpatient drugs at reduced prices, the program empowers healthcare providers to stretch their limited resources, expand care, and address community needs. However, the program is now at a critical crossroads, facing challenges that threaten its sustainability and impact.
Read More: https://340bwell.com/case-studies/understanding-the-lifeline-the-role-a…